Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMQZXDW)

• Drug Name: LUM001 Drug Info
• Synonyms: SHP625

Indication

Disease Entry	ICD 11	Status	REF
Primary biliary cholangitis	DB96.1	Phase 2	[1]
Primary biliary cirrhosis	DB96.1	Phase 2	[2]
Primary sclerosing cholangitis	DB96.2	Phase 2	[3]
Progressive familial intrahepatic cholestasis	5C58.03	Phase 2	[3]
Structural developmental anomalies of liver	LB20.0	Phase 2	[3]

• Cross-matching ID:
  PubChem CID: 9831642
  CAS Number: CAS 228113-66-4
  TTD Drug ID: DMQZXDW
  VARIDT Drug ID: DR01060

Molecule-Related Drug Atlas

Drug(s) Targeting Ileal sodium/bile acid cotransporter (SLC10A2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Odevixibat	DMYN391	Pruritus	EC90	Approved	[5]
Maralixibat	DMJCF1O	Pruritus	EC90	Approved	[5]
A-3309	DM4OHMP	Lipid metabolism disorder	5C52.Z	Phase 3	[6]
S-8921	DMRZA6G	Hyperlipidaemia	5C80	Phase 2	[7]
264W94	DMBOL4K	Hyperlipidaemia	5C80	Phase 2	[8]
GSK2330672	DM4BTH8	Pruritus	EC90	Phase 2	[9]
Taurocholic Acid	DM2LZ8F	Type-2 diabetes	5A11	Phase 1/2	[10]
1614235 + 2330672	DMD751X	Type-2 diabetes	5A11	Phase 1	[11]
AZD-7806	DM34W56	Discovery agent	N.A.	Investigative	[6]

Drug(s) Targeting Sodium/bile acid cotransporter (SLC10A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Bulevirtide	DMJUVE6	Hepatitis D virus infection	1E51.2	Approved	[12]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Ileal sodium/bile acid cotransporter (SLC10A2)	TTPI1M5	NTCP2_HUMAN	Inhibitor	[4]
Sodium/bile acid cotransporter (SLC10A1)	TTWZRY5	NTCP_HUMAN	Inhibitor	[1]

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [2] ClinicalTrials.gov (NCT02321306) An Open-label Study to Evaluate the Long-term Safety and Tolerability of LUM001 in Patients With Primary Biliary Cirrhosis. U.S. National Institutes of Health.
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] Current research on the treatment of primary sclerosing cholangitis. Intractable Rare Dis Res. 2015 Feb; 4(1): 1-6.
• [5] Ileal bile acid transporter inhibition as an anticholestatic therapeutic target in biliary atresia and other cholestatic disorders. Hepatol Int. 2020 Sep;14(5):677-689.
• [6] Elobixibat for the treatment of constipation. Expert Opin Investig Drugs. 2013 Feb;22(2):277-84.
• [7] Inhibition of ileal Na+/bile acid cotransporter by S-8921 reduces serum cholesterol and prevents atherosclerosis in rabbits. Arterioscler Thromb Vasc Biol. 1998 Aug;18(8):1304-11.
• [8] Inhibition of apical sodium-dependent bile acid transporter as a novel treatment for diabetes. Am J Physiol Endocrinol Metab. 2012 Jan 1;302(1):E68-76.
• [9] Discovery of a highly potent, nonabsorbable apical sodium-dependent bile acid transporter inhibitor (GSK2330672) for treatment of type 2 diabetes. J Med Chem. 2013 Jun 27;56(12):5094-114.
• [10] Expression and transport properties of the human ileal and renal sodium-dependent bile acid transporter. Am J Physiol. 1998 Jan;274(1 Pt 1):G157-69.
• [11] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 960).
• [12] Bulevirtide: First Approval. Drugs. 2020 Oct;80(15):1601-1605.